Decreased in-vitro cellular drug resistance by addition of vascular endothelial growth factor receptor (VEGFR) inhibitor, PTK787/ZK 222584, to conventional chemotherapy in pediatric AML.

被引：0
|
作者：
De Bont, ESJM [1 ]
Meeuwsen-de Boer, T [1 ]
Scherpen, F [1 ]
Streefland, E [1 ]
Kamps, WA [1 ]
机构：
[1] Univ Groningen Hosp, Groningen, Netherlands
来源：
LEUKEMIA | 2003年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O40
引用
收藏
页码：668 / 668
页数：1
相关论文
共 32 条
  • [1] The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase
    Banerjee, Susana
    Zvelebil, Marketa
    Furet, Pascal
    Mueller-Vieira, Ursula
    Evans, Dean B.
    Dowsett, Mitch
    Martin, Lesley-Ann
    CANCER RESEARCH, 2009, 69 (11) : 4716 - 4723
  • [2] Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584
    Thomas, AL
    Morgan, B
    Drevs, J
    Unger, C
    Wiedenmann, B
    Vanhoefer, U
    Laurent, D
    Dugan, M
    Steward, WP
    SEMINARS IN ONCOLOGY, 2003, 30 (03) : 32 - 38
  • [3] PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization
    Goldbrunner, RH
    Bendszus, M
    Wood, J
    Kiderlen, M
    Sasaki, M
    Tonn, JC
    NEUROSURGERY, 2004, 55 (02) : 426 - 432
  • [4] Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis
    Schomber, Tibor
    Zumsteg, Adrian
    Strittmatter, Karin
    Crnic, Ivana
    Antoniadis, Helena
    Littlewood-Evans, Amanda
    Wood, Jeanette
    Christofori, Gerhard
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (01) : 55 - 63
  • [5] Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK)
    Drevs, J
    Mross, K
    Reusch, P
    Peng, B
    Ball, H
    Henry, A
    Laurent, D
    Dugan, M
    Marme, D
    Unger, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S283 - S283
  • [6] PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization - Comments
    Piepmeier, JM
    Westphal, M
    NEUROSURGERY, 2004, 55 (02) : 432 - 432
  • [7] Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity
    Yamamoto, Aisaku
    Watanabe, Hideaki
    Sueki, Hirohiko
    Nakanishi, Takako
    Yasuhara, Hajime
    Iijima, Masafumi
    JOURNAL OF DERMATOLOGY, 2007, 34 (07): : 419 - 429
  • [8] Biomarkers (VEGF, BFGF) for assessing the biological activity of PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumours known to overexpress VEGF
    Drevs, J
    Steward, WP
    Dugan, M
    Lee, L
    Laurent, D
    Zirrgiebel, U
    Yung, A
    Rich, J
    Unger, C
    Marme, D
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S78 - S78
  • [9] Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
    Drevs, J
    Zirrgiebel, U
    Schmidt-Gersbach, CIM
    Mross, K
    Medinger, M
    Lee, L
    Pinheiro, J
    Wood, J
    Thomas, AL
    Unger, C
    Henry, A
    Steward, WP
    Laurent, D
    Lebwohl, D
    Dugan, M
    Marmé, D
    ANNALS OF ONCOLOGY, 2005, 16 (04) : 558 - 565
  • [10] Biomarkers for the assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Comparison of preclinical data with results in phase I studies.
    Lee, L
    McSheehy, P
    Morgan, B
    Laird, G
    Allegrini, P
    Cozens, R
    Dugan, M
    Laurent, D
    Lebwohl, D
    Sharma, S
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6203S - 6203S
1234